New antibody therapy targets Hard-to-Treat blood cancers
NCT ID NCT06542250
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tests an experimental drug called AZD5492 in people with B-cell blood cancers that have come back or not responded to at least two prior treatments. The drug is designed to help the body's immune T cells attack cancer cells. The main goals are to check if the drug is safe and to find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGLa Jolla, California, 92093, United States
-
Research Site
WITHDRAWNBoston, Massachusetts, 02215, United States
-
Research Site
RECRUITINGHackensack, New Jersey, 07601, United States
-
Research Site
RECRUITINGNew York, New York, 10021, United States
-
Research Site
RECRUITINGNew York, New York, 10029, United States
-
Research Site
RECRUITINGCharlotte, North Carolina, 28203, United States
-
Research Site
RECRUITINGWinston-Salem, North Carolina, 27157, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGSeattle, Washington, 98109, United States
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
RECRUITINGNedlands, 6009, Australia
-
Research Site
RECRUITINGCalgary, Alberta, T2N 5G2, Canada
-
Research Site
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Research Site
RECRUITINGMontreal, Quebec, H3T 1R2, Canada
-
Research Site
RECRUITINGHangzhou, 310003, China
-
Research Site
RECRUITINGShanghai, 200025, China
-
Research Site
RECRUITINGKøbenhavn Ø, 2100, Denmark
-
Research Site
RECRUITINGPessac, 33604, France
-
Research Site
RECRUITINGVillejuif, 94805, France
-
Research Site
RECRUITINGMünchen, 81675, Germany
-
Research Site
RECRUITINGUlm, 89081, Germany
-
Research Site
RECRUITINGWürzburg, 97080, Germany
-
Research Site
RECRUITINGBologna, 40138, Italy
-
Research Site
RECRUITINGMilan, 20133, Italy
-
Research Site
RECRUITINGChūōku, 104-0045, Japan
-
Research Site
RECRUITINGKashiwa, 277-8577, Japan
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGL'Hospitalet de Llobregat, 08908, Spain
-
Research Site
RECRUITINGMadrid, 28040, Spain
Conditions
Explore the condition pages connected to this study.